Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2021-08-05 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings
2021-08-05 English
Financial Result Updates
Regulatory Filings
2021-08-05 English
Outcome of Board Meeting
Regulatory Filings
2021-08-05 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 100% confidence The document text is extremely short (113 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, this document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2021-07-27 English
Book Closure
Regulatory Filings
2021-07-26 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, specifically detailing related party transactions for the half-year ended March 31, 2021. It includes names of related parties, key managerial personnel, relatives, and enterprises influenced by them, along with the transactions carried out during the period. The document is a regulatory disclosure about related party transactions, which is a compliance requirement but does not constitute a full financial report or audit report. It is not an annual or interim report, earnings release, or management discussion. Given the nature of the document as a regulatory disclosure under SEBI listing regulations and its focus on related party transactions, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.